We are carrying out application-oriented research of low-molecular-weight compounds (hit compounds and lead compounds) developed at our laboratory through academic drug discovery programs, and our goal is to acquire POC in investigator-initiated clinical trials.

We are mainly working on the following projects.

1. Development of antiviral drugs that are effective against existing drug resistant viruses

We are implementing non-clinical studies (pharmacological studies, safety pharmacology studies, toxicity studies, pharmacokinetics studies, and all CMC work) necessary for investigator-initiated clinical trial of CDK9 inhibitor FIT 039 showing antiviral effect against HPV, and investigator-initiated clinical trial (POC trial) on patients with viral warts, through regulatory strategy consultation with Pharmaceuticals and Medical Devices Agency (PMDA). We are also advancing the negotiations for licensing and joint development with pharmaceutical companies and others. We are also conducting nonclinical studies for investigator-initiated clinical trials that have been expanded to include cervical cancer as an adaptation disease.

2. Splicing control drugs that can be used for treating genetic disorders

We are implementing non-clinical studies for lead compounds (splicing control) directed at practical application of therapeutic drugs for Familial Dysautonomia and Fabry Disease.

3. Down syndrome causative kinase DYRK1A inhibitor

We are implementing non-clinical studies for hit compounds/lead compounds (DYRK1A inhibitor). We are also working on selecting the target diseases.

4. Research on pain-relieving drugs that do not have the side effects of current opioid analgesics

We are implementing non-clinical studies for investigator-initiated clinical trials for a lead compound we discovered that has a strong analgesic effect in monkeys, as a cancer pain reliving drug.

5. Research on a new anticancer drug that targets only specific cancer cells while protecting healthy cells

We are implementing non-clinical studies for investigator-initiated clinical trial for a lead compound we discovered having an antitumor effect in mice, as an antitumor drug.